Hexavalent vaccines | NITAG RESOURCE CENTER

Proportion of the population affected by the disease or infected with the antigen

NOT RELEVANT FOR CURRENT DECISIONS - PLEASE CONSULT THE RELEVANT WHO POSITION PAPERS. ^{Go to footnote 11, Go to footnote 22, Go to footnote 33, Go to footnote 44, Go to footnote 55, Go to footnote 66} For disease burden for relevant diseases (at least D,T,P) countries can consult the WHO JRF data for their country, or subregion per WHO JRF. ^{Go to footnote 77}

Sources

Go back to footnote reference 1
Diphtheria vaccine: WHO position paper, August 2017. Weekly Epidemiological Record. 2017; 92(31): 417–435.
Go back to footnote reference 2
Tetanus vaccine: WHO position paper, February 2017. Weekly Epidemiological Record. 2017; 92(6): 53–76.
Go back to footnote reference 3
Pertussis vaccine: WHO position paper, August 2015. Weekly Epidemiological Record. 2015; 90(35): 433–460.
Go back to footnote reference 4
Hepatitis B vaccines: WHO position paper, July 2017. Weekly Epidemiological Record. 2017; 92(27): 369–392.
Go back to footnote reference 5
Haemophilus influenzae type b (Hib) vaccine: WHO position paper, July 2013. Weekly Epidemiological Record. 2013; 88(39): 413–426.
Go back to footnote reference 6
Polio vaccines: WHO position paper, June 2022. Weekly Epidemiological Record. 2022; 97(25): 277–296.7.
Go back to footnote reference 7
Global immunization data. In: World Health Organization [website]. Geneva: World Health Organization; n.d. (https://immunizationdata.who.int/global?topic=&location=, accessed 11 July 2025).